Pharming B.V.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Pharming B.V.
Live alerts from global media, monitored by Business Radar
2025-06-24 (beurs.nl)
Pharming reports more APDS patients than previously accepted
Pharming Group has published a new study in the Medical Journal Cell, which shows that APDS may occur more often than previously assumed. The biotech company reported this on Tuesday.
Read more
2021-09-14 (skipr.nl)
Pharming wants follow -up study with Ruconest in corona patients -
The Leiden biotechnologist Pharming wants to start new research into the functioning of the agent Ruconest against the effects of COVID-19, the disease caused by the Coronavirus. Two small -scale studies in Switzerland and in the United States offered enough tools for further research, according to the company.
Read more
2017-09-11 (deaandeelhouder.nl)
Pharming takes a new step in the development of Ruconest
Pharming Group has completed the so-called FDA end phase 2 interactions regarding the prophylaxis indication for its anti-angioedema drug Ruconest. The biotech company announced this on Monday. Part of the completion was the ter
Read more
2017-09-11 (deaandeelhouder.nl)
Pharming takes a new step in the development of Ruconest
Pharming Group has completed the so-called FDA end phase 2 interactions regarding the prophylaxis indication for its anti-angioedema drug Ruconest. The biotech company announced this on Monday. Part of the completion was the ter
Read more
(morningstar.com)
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan
LEIDEN, The Netherlands, Aug.9, 2023 /PRNewswire/ -- Pharming Group N.V.( `` Pharming '' or `` the Company '')( EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial in Japan evaluating leniolisib for the treatment of activated
Read more